NEW YORK, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)ISRAEL CANCER RESEARCH FUND INC, founded in 1975, is a community nonprofit that reported $7.7M in total revenue in fiscal year 2023. Revenue surged 35% from the prior year, signaling strong growth momentum. The organization ran a surplus of $1.4M, a strong 18% operating margin.
TO SUPPORT CANCER RESEARCH IN ISRAEL, FOR THE BENEFIT OF ISRAEL AND ALL MANKIND.
PROVIDE CANCER RESEARCH FUNDING FOR ISRAELI SCIENTISTS. ICRF IS THE LARGEST NON-PROFIT IN NORTH AMERICA DEDICATED TO SUPPORTING CANCER RESEARCH IN ISRAEL. OVER THE LAST NEARLY 50 YEARS, ICRF HAS...
PROVIDE CANCER RESEARCH FUNDING FOR ISRAELI SCIENTISTS. ICRF IS THE LARGEST NON-PROFIT IN NORTH AMERICA DEDICATED TO SUPPORTING CANCER RESEARCH IN ISRAEL. OVER THE LAST NEARLY 50 YEARS, ICRF HAS PROVIDED MORE THAN $93 MILLION TO SUPPORT CANCER RESEARCH IN ISRAEL, FUNDING OVER 2,700 RESEARCH PROJECTS. IN 2023, WE AWARDED 57 RESEARCH GRANTS VALUED AT NEARLY $3.4M. TYPICALLY, 60-80 GRANTS ARE FUNDED ANNUALLY, BASED ON AN EVALUATION AND PRIORITIZATION BY INDEPENDENT REVIEW PANELS CONSISTING OF 40-50 LEADING CANCER SCIENTISTS FROM NORTH AMERICAN BIOMEDICAL RESEARCH CENTERS. ICRF GRANT CATEGORIES ARE TAILORED TO SUPPORT CANCER RESEARCHERS AT ALL OF THE VARIOUS STAGES OF THEIR CAREERS, AND WE ARE PROUD TO HAVE HELPED SUPPORT MANY OF TODAY'S MOST OUTSTANDING SCIENTISTS AT THE EARLIEST STAGES IN THEIR CAREERS. ICRF SEEKS TO CAPITALIZE ON THE SIGNIFICANTLY LOWER COSTS OF CONDUCTING CANCER RESEARCH IN ISRAEL. ALL AWARDS GO DIRECTLY TO THE DESIGNATED RESEARCHER WITHOUT ANY REDUCTION FOR OVERHEAD. IN 2021, WE AWARDED 49 RESEARCH GRANTS VALUED AT NEARLY $2.795M.
SUPPORT THE DEVELOPMENT OF THE NEXT GENERATION OF ISRAELI CANCER SCIENTISTS. ICRF IS COMMITTED TO FACILITATING THE DEVELOPMENT OF FUTURE CANCER SCIENTISTS IN ISRAEL. TOWARDS THIS END ICRF FUNDS THREE...
SUPPORT THE DEVELOPMENT OF THE NEXT GENERATION OF ISRAELI CANCER SCIENTISTS. ICRF IS COMMITTED TO FACILITATING THE DEVELOPMENT OF FUTURE CANCER SCIENTISTS IN ISRAEL. TOWARDS THIS END ICRF FUNDS THREE TYPES OF GRANTS: POSTDOCTORAL FELLOWSHIP AWARDS, RESEARCH CAREER DEVELOPMENT AWARDS, AND CLINICAL RESEARCH CAREER DEVELOPMENT AWARDS. FELLOWSHIPS SUPPORT MDS AND PHDS WHO HAVE JUST COMPLETED THEIR POSTGRADUATE TRAINING. THESE AWARDS CAN BE USED TO SUPPORT SALARIES OR RESEARCH COSTS, WHILE THESE INDIVIDUALS APPRENTICE IN THE LABORATORIES OF SENIOR INVESTIGATORS. CAREER DEVELOPMENT AWARDS ARE TO ENHANCE THE RESEARCH CAPABILITIES OF YOUNG ISRAELI SCIENTISTS IN THE FORMATIVE PHASE OF THEIR CAREERS. CANDIDATES MUST HAVE DEMONSTRATED OUTSTANDING POTENTIAL FOR CONTRIBUTIONS TO CANCER RESEARCH AND MUST EXHIBIT GREAT POTENTIAL TO BECOME INDEPENDENT INVESTIGATORS RESEARCH. SUPPORTING THESE NEWLY LAUNCHED SCIENTISTS, ENHANCES THEIR OPPORTUNITIES IN ISRAEL AND ALLOWS THEM TO OPTIMIZE THEIR WORK WITHOUT EMIGRATING TO OTHER ADVANCED COUNTRIES.
SUPPORT COLLABORATIVE CANCER RESEARCH CONDUCTED BY ISRAELI SCIENTISTS IN ASSOCIATION WITH NORTH AMERICAN CANCER SCIENTISTS. CANCER SCIENCE OFTENTIMES REQUIRES MULTI-DISCIPLINARY APPROACHES...
SUPPORT COLLABORATIVE CANCER RESEARCH CONDUCTED BY ISRAELI SCIENTISTS IN ASSOCIATION WITH NORTH AMERICAN CANCER SCIENTISTS. CANCER SCIENCE OFTENTIMES REQUIRES MULTI-DISCIPLINARY APPROACHES, ENGAGEMENT WITH HIGHLY SPECIALIZED AREAS OF SCIENCE, AND EXPENSIVE EQUIPMENT THAT IS NOT EASILY ACCESSED. COLLABORATIONS BETWEEN SCIENTISTS IN ISRAEL AND NORTH AMERICA CAN ADDRESS THESE CHALLENGES, FOSTER UNEXPECTED SYNERGIES, AND ENHANCE BOTH INTELLECTUAL CURIOSITY AND INNOVATION. ICRF PROMOTES COLLABORATION BY SUPPORTING GRANTS THAT FUND PROMISING CANCER RESEARCH PROJECTS BEING CONDUCTED ON A COLLABORATIVE BASIS BETWEEN INVESTIGATORS IN ISRAEL AND AN AMERICAN OR CANADIAN RESEARCH INSTITUTION.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $7,728,171 | $5,734,601 | +0.3% |
| Expenses | $6,353,295 | $6,217,607 | +0.0% |
| Net Income | $1,374,876 | $-483,006 | -3.8% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| DAVID ABRAMSON | PRESIDENT | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| BRYNA GOLDBERG | CHAIR | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| ARNOLD M BASKIES MD | VICE PRESIDENT | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| NANCY MAIZELS PHD | VICE PRESIDENT | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| RICHARD EDELHEIT | TREASURER | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| CYNTHIA PERL | SECRETARY | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| JORDANNA FEIFER | EXECUTIVE COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| BONNIE E FISH | EXECUTIVE COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| LESLIE FREEDMAN | EXECUTIVE COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| LISA OVED | EXECUTIVE COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| CHARLES SERLIN | EXECUTIVE COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| ROBERT BARD | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| BRUCE BARRON | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| ALAN BERK | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| CHARLES BEN DAYAN | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| JEFFREY BERNSTEIN | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| JEFFREY BLY | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| MICHELLE CHREIN | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| MARSHA DEAKTER | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| ROB DENSEN | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| VERA FINKELSTEIN | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| PAUL T FOX | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| TAMIR GILAT | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| BRAD GOLDHAR | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| KENNETH E GOODMAN | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| GARY I GRAD MD | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| ROBERT GREENE | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| MARYANNE GREENFIELD | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| SAMUEL HERZFELD | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| MARK A ISRAEL MD | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| BARBARA KASELL | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| SUSAN MATTESON KING | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| RICHARD LIPKIN | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| MICHELLE MAKORI | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| DAVID MALKIN MD | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| LEN MARK | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| PATRICK MUNDT | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| JOEL PELOFSKY | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| TOM PELED | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| GERELD SOFF MD | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| JULIA WEKSLER | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| SIDNEY J WINAWER MD | TRUSTEE | 2.00 |
Director
|
$0 | $0 | $0 |
| BERYL CHERNOV | NATIONAL EXECUTIVE DIRECTOR | 40.00 |
Officer
|
$325,941 | $69,497 | $395,438 |
| ALLYSON MARKS-GREENFIELD | EXECUTIVE DIRECTOR, CHICAGO | 40.00 |
Key Emp
|
$152,770 | $35,627 | $188,397 |
| ALAN HERMAN | EXECUTIVE DIRECTOR, NEW YORK | 40.00 |
Key Emp
|
$215,128 | $74,760 | $289,888 |
| TANIA ORENSTEIN | CONTROLLER | 40.00 |
Key Emp
|
$165,890 | $12,610 | $178,500 |
| DAVID KWESKIN | CONNECTICUT DIRECTOR | 40.00 |
Highest
|
$114,762 | $7,917 | $122,679 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $7,728,171 | $6,353,295 | $19,252,119 | $1,374,876 |
| 2022 | $5,734,601 | $6,217,607 | $16,331,164 | $-483,006 |
| 2021 | $7,146,502 | $5,411,705 | $17,015,756 | $1,734,797 |
| 2020 | $4,713,669 | $5,312,259 | $15,265,457 | $-598,590 |
| 2019 | $7,723,480 | $4,911,851 | $15,745,810 | $2,811,629 |
| 2018 | $3,897,018 | $5,704,307 | $13,165,186 | $-1,807,289 |
Compare ISRAEL CANCER RESEARCH FUND INC with other nonprofits in New York and across the country.